Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
PURPOSE: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in progression-free survival (PFS) in advanced non-small cell lung cancer in three randomized phase II studies: vandetanib versus gefitinib (study 3), docet...
主要な著者: | Hanrahan, E, Ryan, A, Mann, H, Kennedy, S, Langmuir, P, Natale, R, Herbst, R, Johnson, B, Heymach, J |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2009
|
類似資料
-
Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
著者:: Heymach, J, 等
出版事項: (2008) -
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
著者:: Hanrahan, E, 等
出版事項: (2010) -
Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime? Response
著者:: Hanrahan, E, 等
出版事項: (2010) -
Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
著者:: Jr, W, 等
出版事項: (2012) -
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
著者:: Wells, SA, 等
出版事項: (2012)